anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Atrial Fibrillation (AF) is the most common arrhythmia and is associated with significant healthcare-related expenses. With the aging population, the prevalence of AF is increasing. AF frequently co-exists with heart failure (HF) with reduced (HFrEF) or preserved (HFpEF) ejection fraction. The relationship between AF and HF is complex, and one condition constitutes a risk factor for the other. Myocardial interstitial fibrosis is a hallmark of myocardial remodeling occurring as a consequence of risk factor exposure leading to both AF and heart failure. However, the role of interstitial fibrosis in the prognosis of patients with atrial fibrillation with and without heart failure remains unknown.

AF has a significant impact on patients' well-being and quality of life. In addition to coping with uncomfortable symptoms, individuals with this condition face an increased risk of future adverse events like frailty, stroke, dementia, and all-cause mortality. To address these concerns, many patients opt for procedures such as AF ablation, hoping for a cure. While the results of this procedure show promise, a small percentage of patients who undergo AF ablation may experience a recurrence of the arrhythmia or find that the participant's heart's systolic function does not fully recover. The investigators aim is to investigate whether there is a connection between myocardial fibrosis and poor outcomes following AF ablation.

Cardiac MRI (CMR) has been the gold standard methodology of quantification of interstitial fibrosis. Diffuse interstitial fibrosis can be quantified by extracellular volume (ECV) imaging. CMR-based left ventricular ECV has been associated with adverse outcomes in multiple cardiovascular disease states. However, the availability of CMR is confined only to tertiary centers with expertise. Cardiac CT is an alternative way to detect and quantify interstitial fibrosis by quantification of ECV. CT-derived ECV has been shown in multiple studies to have an excellent correlation with CMR-derived ECV. Cardiac CT is widely available and has a higher spatial resolution. Since as part of the standard pre-ablation routine, patients will undergo a cardiac CT scan to accurately map the anatomy of the participant's heart, investigators ought to measure ECV parameters during this visit.
The invention provides a trimetazidine hydrochloride mono-layer osmotic pump controlled release tablet and a preparation method thereof. The tablet is composed of a core, a coating membrane, and pores. The core comprises the following components, by weight percentage: 10-25% of trimetazidine hydrochloride, 8-35% of an osmotic pressure active substance, 16-50% of a suspension, 12-47% of a filler, and 0.5-1.5% of a lubricant. The coating membrane comprises, every 100 tablets: 1-10g of a pore forming agent, 1-10g of a plasticizer, 10-40g of a film forming material, and a proper amount of an solvent. The weight gain of the coating membrane is 4-10% of the weight of the core. The diameter of each pore is in a range of 0.6-1.2 mm. According to the trimetazidine hydrochloride mono-layer osmotic pump controlled release tablet, the auxiliary materials are high in security; the release accords with zero-level release; stability of a plasma concentration can be maintained; frequency of medicine administration for a patient is reduced; and the toxic and side effect of the medicine is minimized. The preparation method is simple, and the raw materials are less, so that the preparation method is suitable for industrial production.
1\. Take one pill at the same time every day until you have taken the last pill in the wallet.

Do not skip pills even if you are spotting or bleeding or feel sick to your stomach (nausea). Do not skip pills even if you do not have sex very often.

2\. WHEN YOU FINISH A WALLET.

After taking the last white pill, start taking the first pink pill from a new Extended-Cycle Wallet the very next day regardless of when your period started. This should be on a Sunday.

3\. If you miss your period when you are taking the white pills, call your healthcare provider because you may be pregnant.
Patients who are undergoing physical rehabilitation, benefit from feedback that follows from reliable assessment of their cumulative performance attained at a given time. In this paper, we provide a method for the learning of the recovery trajectory of an individual patient, as they undertake exercises as part of their physical therapy towards recovery of their loss of movement ability, following a critical illness. The difference between the Movement Recovery Scores (MRSs) attained by a patient, when undertaking a given exercise routine on successive instances, is given by a statistical distance/divergence between the (posterior) probabilities of random graphs that are Bayesianly learnt using time series data on locations of 20 of the patient's joints, recorded on an e-platform as the patient exercises. This allows for the computation of the MRS on every occasion the patient undertakes this exercise, using which, the recovery trajectory is drawn. We learn each graph as a Random Geometric Graph drawn in a probabilistic metric space, and identify the closed-form marginal posterior of any edge of the graph, given the correlation structure of the multivariate time series data on joint locations. On the basis of our recovery learning, we offer recommendations on the optimal exercise routines for patients with given level of mobility impairment.
BACKGROUND: Severe heterotopic ossification (HO) (grades III and IV) after total hip arthroplasty (THA) over the last 25 years requiring excision is very uncommon. We performed a systematic review of the literature and reported a new case series with operative treatment after primary uncemented THA.
METHODS: A systematic review identified papers describing patients who had excision of HO after THA performed after 1988. Concepts of hip arthroplasty, HO, and surgical excision were searched in MEDLINE, Embase, and Scopus from database inception to November 2022. The inclusion criteria were articles that included specific patient data on the grade of HO, operative procedure, and prophylaxis. Studies were screened for inclusion by 2 independent reviewers. The extracted data included demographic data, the interval from index surgery to excision, clinical results, and complications. There was one surgeon who performed reoperation for ankylosis of primary THA in 3 men who had severe pain and hip deformity.
RESULTS: Data from 7 studies were included. There were 41 patients who had grade III or IV HO who had excision, and in 5 patients, revision of a component was also performed. Perioperative prophylaxis was irradiation alone in 10 patients, irradiation and indomethacin in 10 patients, and indomethacin alone in 21 patients. At a mean follow-up time of 14.8 months, the definition of the results was not uniform, and range of motion was improved, but relief of pain was inconsistent. There was one dislocation after resection without revision, one gastrointestinal complication, and 2 recurrences. Treatment of the 3 new patients, with wide excision of periarticular bone, selective exchange of components, and perioperative irradiation prophylaxis, was successful in improving pain, motion, and deformity.
CONCLUSIONS: There is insufficient good-quality data on the operative treatment of severe symptomatic HO after THA performed over the last 25 years. Prophylaxis with low-dose irradiation prevented a recurrence. Multicenter studies are needed to determine the optimum timing and prognosis for treatment.
Cancer is a leading cause of mortality in the United States. While strong USPSTF guideline recommendations support appropriate screening for early detection and to avoid preventable deaths, breast cancer screening is often underutilized. Increasing breast cancer screening rates is challenging, in part, because it requires complementary decisions from clinicians (e.g., recommend and counsel patients about screening) and patients (e.g., to internalize risks and choose to complete screening). Presently, the lack of interventions directly targeting both clinicians' and patients' decision-making may underscore the relatively stagnant screening rates in the United States. There is a significant need to develop and scale low-cost interventions that increase breast cancer screening while simultaneously addressing the needs of high-risk patients and reducing disparities. Building upon prior work, the investigators propose to develop and test EHR-based clinician and patient nudges, with an additional intensified nudge to high-risk patients, to help increase screening mammography rates.

This study consists of two complementary and concurrent, cluster-randomized, pragmatic trials to be conducted at Penn and UH.
The present invention relates to an isolated immunogenic peptide chimera comprising a first peptide moiety comprising the amino acid sequence of SEQ ID NO: 1, or at least a contiguous 5 amino acid fragment thereof, a second peptide moiety comprising the amino acid sequence of SEQ ID NO: 2, or at least a contiguous 5 amino acid fragment thereof, and a linker joining the first and second peptide moieties, wherein the first peptide moiety is at the immunogenic peptide chimera's N-terminus and the second peptide moiety is at the immunogenic peptide chimera's C-terminus. Also disclosed is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 6, or at least a contiguous 5 amino acid fragment thereof, having a length sufficient to form β-hairpin structure. A further aspect of the present invention is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 15, or at least a contiguous 5 amino acid fragment thereof, capable of folding into an alpha-helical structure. These immunogenic peptides can be inserted into an immunogenic scaffold protein to form an immunogenic polypeptide. The immunogenic peptides or immunogenic polypeptides can be used in an immunogenic vaccine composition and in methods of inducing a neutralizing antibody response, or inducing a protective and non-neutralizing antibody response, or protective antibodies, against HIV-1 gp120 in a subject. Isolated antibodies and methods of detecting are also disclosed.
PURPOSE: To assess the risk factors for thrombosis in the pulmonary vein stump (PVT) and the efficacy of proximal ligation in preventing PVT after lobectomy.
METHODS: In total, 649 surgical patients with lung cancer were retrospectively reviewed. To compare the clinical effectiveness of PV proximal ligation, the simple stapler group (290 patients) and the proximal ligation group (359 patients who underwent thread ligation at the pericardial reflection with/without a stapler) were analyzed.
RESULTS: In the simple stapler group, 12 of 290 patients (4.1%) developed PVT. Among these, 9 of 58 underwent left upper lobectomy (LUL). In contrast, 5 of the 359 patients (1.4%) in the proximal ligation group developed PVT. All five patients received LUL. The incidence of PVT in the proximal ligation group was significantly lower than that in the simple stapler group (p = 0.0295) as well as in the analysis by LUL alone (p = 0.0263). A logistic regression analysis indicated that higher BMI and LUL were associated with the development of PVT (p = 0.0031, p < 0.0001), and PV proximal ligation reduced PVT (p = 0.0055).
CONCLUSION: Proximal ligation of the PV has the potential to prevent PVT, especially after LUL.
The aim of this study is to investigate the effect of intrastromal fresh corneal lenticule implantation using Smile module surgery after PK with primary objective to increase visual acuity by reducing irregular astigmatism according to high K values. The stromal pocket diameter was 8 mm, 2mm super incision, 140-µm cap thickness and fresh lenticular implantation is performed.
Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, LPV/r on Days 22 to 35, and LPV/r plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 35, and 42.
Landmark trials in Crohn's disease demonstrated the efficacy of infliximab in inducing and maintaining clinical remission. Furthermore, the endoscopic sub-studies within these trials demonstrated the ability of infliximab to rapidly induce and maintain mucosal healing as evidenced by the complete absence of mucosal breaks in the colon and terminal ileum. Unfortunately, conventional colonoscopy does not allow intestinal exploration beyond a very restricted portion of the small bowel (at most 10-15 cm of the terminal ileum). A study that systematically examines the changes in the small bowel mucosa during Crohn's disease symptomatic improvement is clearly needed.

This study consists of 20 subjects and 30 weeks of follow up. All subjects will undergo wireless camera endoscopy at three (3) visits, namely: at Screening, at Week 10 and at Week 26. Infliximab is administered at (5) visits, namely: at Baseline (week 0), Week 2, Week 6, Week 14 and Week 22. In some subjects, an ileal-colonoscopy may be performed at Week 26.
Disclosed herein is an antibacterial cleansing composition. The cleansing composition is free of triclosan and comprises lactic acid/lactate and ethyl alcohol. Lactic acid/lactate is present in the composition in an amount of about 5 weight percent (wt %) to about 15 wt %, based on the total weight of the composition. Ethyl alcohol is present in an amount of about 1 wt % to about 20 wt %, based on the total weight of the composition. The pH of the composition is about 4 to about 5. The triclosan-free cleansing composition according to the invention has broad spectrum antibacterial activity that equals or even surpasses comparable formulations containing triclosan.
The invention relates to a pure traditional Chinese medicine composition, and in particular to a newborn diaper dermatitis lotion. Every 250 ml of newborn diaper dermatitis lotion comprises, by weight, 15-25 g of fructus cnidii, 15-25 g of fructus kochiae, 15-25 g of schizonepeta, 15-25 g of the divaricate saposhnikovia root, 15-25 g of golden cypress, 15-25 g of radix sophorae flavescentis, 15-25 g of cortex dictamni, 10-20 g of dandelion, 10-20 g of violae, 5-15 g of the pine needle, 5-15 g of borneol, 2-6 g of vitamin E and 15-25 g of mint. Main ingredients of the newborn diaper dermatitis lotion comprise the divaricate saposhnikovia root, the fructus kochiae, the pine needle and the like; the newborn diaper dermatitis lotion has the effects of clearing away heat and toxic materials, killing parasites to stop pains, promoting the circulation of qi to eliminate blood stasis and the like, and skin irritation and toxic and side effects are avoided. After the newborn diaper dermatitis lotion is used, scytitis is resolved, and exudation is reduced. Pains of a child patient are reduced, and the child patient can calm down rapidly; and meanwhile, through the effect of promoting the circulation of qi to eliminate blood stasis, partial microcirculation of an erosion face can be improved, the partial blood flow is increased, and rapid regeneration and repairing of a wound face are promoted. The newborn diaper dermatitis lotion further has the beneficial effects that the newborn diaper dermatitis lotion is easy, convenient and low in cost, and the child patient can be treated at home.
Disclosed is a patient monitoring and drug delivery system and associated methods for use during diagnostic, surgical or other medical procedures. The functionality of 5 the invention enables many time consuming and laborious activities to be minimized or moved to a part in the procedure where time is not as critical. The invention is capable of increasing practice efficiency in patient care facilities through system architecture and design into two separate units. A patient unit receives input signals from patient monitoring connections and outputs the signals to a procedure unit. The 10 procedure unit is operational during the medical procedure and controls the delivery of drugs to the patient. Drawing to be used with the abstract is Fig. 3. 04/06/09.va 18012 abstract,2 LrCL <0 Nx uii
Excessive pregnancy-related weight retention is an important determinant of obesity and is more common among African American women. At the same time, breastfeeding, which has been recommended as a strategy to decrease weight retention is lowest among African American women. This racial disparity in breastfeeding may partly explain the disparity in obesity, but even if the two are not causally related, a dual intervention designed to increase breastfeeding duration and decrease postpartum weight retention makes practical sense because both are associated with the same critical postpartum time window.

For this study, the investigators will incorporate a postpartum weight management component into an effective breastfeeding support program. This dual intervention will use a combination of in-person, telephone, and interactive web/mobile-based health counseling to provide education and support for breastfeeding difficulties and postpartum weight management. The intervention will be delivered by peer counselors who will be trained to provide support using motivational interviewing techniques with consultation by experts. The investigators have designed the dual intervention to provide encouragement, information, and problem-solving assistance at the appropriate pre or postpartum stage for both breastfeeding support and maternal weight management. The mixed delivery mode has proven effective in other settings and is important to build a trusting relationship while allowing frequent and flexible methods for communicating during this vulnerable time in a new mom's life. The overall goal of this developmental/exploratory R21 proposal is to gather pilot data to effectively refine the intervention so that it can be tested in a larger, longer study using a factorial design in a future R01 phase. The investigators will recruit, in one large inner-city prenatal care clinic (Henry Ford Health System, Detroit, MI), pregnant African American women (32-36 weeks gestation) who are considering breastfeeding (n=80), randomize them to the intervention or to a usual care group, and follow all participants to 20 weeks postpartum. The specific aims are to: 1) test feasibility; 2) assess acceptability; and 3) estimate the effect size of the intervention at 20 weeks postpartum relative to the usual care group on (1) breastfeeding duration and (2) postpartum weight retention. This project is significant because the combined intervention is designed to work synergistically on two interrelated, highly prevalent problems that disproportionately disadvantage African American families.
LIT will be performed identical to Arm 1, except for switchover of active LIT and Sham. A washout period of 1 month will be scheduled to diminish carryover effects of the LIT arm.
Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
Malignant insulinoma is an extremely rare type of functioning pancreatic neuroendocrine tumour with a high degree of malignancy and a high incidence of metastasis. However, it is still unclear how malignant insulinomas develop and metastasize. Serum amyloid P component (SAP), a member of the pentraxin protein family, is an acute-phase protein secreted by liver cells. The role of SAP in insulinoma and the related mechanism are still unknown. To determine the effect of SAP on insulinoma, we crossed Rip1-Tag2 mice, which spontaneously develop insulinoma, and SAP knockout (KO) mice to generate Rip1-Tag2;SAP-/- mice. We found that SAP deletion significantly promoted the growth, invasion and metastasis of malignant insulinoma through C-X-C motif chemokine ligand 12 (CXCL12) secreted by cancer-associated fibroblasts (CAFs). Further study showed that SAP deletion promoted CXCL12 secretion by CAFs through the CXCR4/p38/ERK signalling pathway. These findings reveal a novel role and mechanism of SAP in malignant insulinoma and provide direct evidence that SAP may be a therapeutic agent for this disease.
Days 1 to 3 will include the acquisition phase where the opioid medication will be prescribed on a schedule of 3-4 times per day and paired with an open-label placebo. Day 4 and 6 will be the evoked phase, and patients will receive only the open-label placebo pill. On day 5 the opioid medication will be re-introduced as pharmacological reinforcement.
The invention discloses a traditional Chinese medicine health care food for relieving physical fatigue and a preparation method thereof. The health care food is prepared by five pure traditional Chinese medicine raw materials including flatstem milkvetch seed, semen cuscutae, herba epimedii, rhizoma polygonati and American ginseng. The raw materials are as follows in parts by weight: 20-50 parts of flatstem milkvetch seed, 20-40 parts of semen cuscutae, 5-20 parts of herba epimedii, 5-20 parts of rhizoma polygonati and 1-6 parts of American ginseng. The raw materials are orderly treated by preparation methods such as pretreatment, alcohol extraction, water extraction, thick paste mixing, spray-drying, crushing, mixing, filling, polishing, packing and the like so as to obtain an oral capsule preparation. The traditional Chinese medicine health care food disclosed by the invention has reasonable components and balanced effect, plays an overall regulation advantage and regulates the function of each visceral organ in the whole body, so the traditional Chinese medicine health care food is a good pure traditional Chinese medicine health care food that is helpful to relieve physical fatigue, also causes no untoward effects, has high safety even being taken for a long time, and causes no dependency. The preparation method related to the invention is simple, low in cost and capable of realizing industrial production.
The invention relates to a skin care product or external embrocation (GuYanfen healing panacea for short) for preventing skin rhagades, which is a skin care product or an external preparation (i.e. the external embrocation) prepared by using prophyta cut-and-grow melons as the raw material. Particularly, the skin care product or the external preparation (i.e. the external embrocation) is prepared by using bleeding sap of the prophyta cut-and-grow melons as the raw material and can also be prepared by using one type or a plurality of types of roots, stems, leaves and fruits of the prophyta cut-and-grow melons as the raw material. In the invention, healing prime (the bleeding sap) of the cut-and-grow melons is used as the skin care product or a single-component preparation (i.e. the external embrocation) for preventing or preventing and treating skin rhagades and scars; the total effective rate of the skin care product or the external embrocation reaches over 95 percent, even 100 percent; and the skin care product or the external embrocation is an original ecological and pure natural green product and has the advantages of single raw material, low cost, convenience in using, obvious prevention and treatment effect, no toxic or side effects and capability of effectively preventing and treating the skin rhagades and the scars.
Group 2/B will use the BIP Foley (latex or silicone) during the first \~6 months (observational period 1). Then the patients in this group will switch to the standard catheter and be observed for another \~6 months (the second observational period).
PROBLEM TO BE SOLVED: To prepare a cosmetic having preventing effect from getting older and beautifying effect at the same time, an having high safety. SOLUTION: This cosmetic contains an extract of a kind of mushroom, e.g. Cynomorium coccineum L. or Cynomorium songaricum Rupr. which grows naturally mainly in Korea, China, etc. The extract is available as a commercial product. The cosmetic can be produced in a form of a base cosmetic such as a cream, a lotion, a milky lotion or a pack, a makeup cosmetic such as a foundation or a lip stick, a bath liquid, a soap, etc.